The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
MMP‐2 alters VEGF expression via αVβ3 integrin‐mediated PI3K/AKT signaling in A549 lung cancer cells
Open accessAbstract
Vascular endothelial growth factor (VEGF) is one of the most important angiogenic growth factors for tumor angiogenesis. Here, we sought to explore whether RNA interference (RNAi) targeting matrix metalloproteinase‐2 (MMP‐2) could disrupt VEGF‐mediated angiogenesis in lung cancer. MMP‐2 siRNA inhibited lung cancer cell‐induced tube formation of endothelial cells in vitro; addition of recombinant human‐MMP‐2 restored angiogenesis. MMP‐2 transcriptional suppression decreased VEGF, phosphatidylinositol 3‐kinase (PI3K) protein levels and AKT phosphorylation in lung cancer cells. In addition, MMP‐2 suppression decreased hypoxia inducible factor‐1α (HIF‐1α), a transcription factor for VEGF, as determined by electrophoretic mobility shift assay (EMSA). We also show that MMP‐2 suppression disrupted PI3K dependent VEGF expression; ectopic expression of myr‐AKT restored VEGF inhibition. Further, MMP‐2 suppression decreased the interaction of integrin‐αVβ3 and MMP‐2 as confirmed by immunoprecipitation analyses. Studies with either function blocking integrin‐αVβ3 antibody or MMP‐2 specific inhibitor (ARP‐100) indicate that suppression of MMP‐2 decreased integrin‐αVβ3‐mediated induction of PI3K/AKT leading to decreased VEGF expression. Moreover, A549 xenograft tissue sections from mice that treated with MMP‐2 siRNA showed reduced expression of VEGF and the angiogenic marker, factor‐VIII. The inhibition of tumor angiogenesis in MMP‐2 suppressed tumor sections was associated with decreased co‐localization of integrin‐αVβ3 and MMP‐2. In summary, these data provide new insights into the mechanisms underlying MMP‐2‐mediated VEGF expression in lung tumor angiogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
Risau, W. (1997) · Nature · doi:10.1038/386671a0 · Cited by 5,727
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C., & Semenza, G. L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.3995-4004.2001 · Cited by 1,256 · cited 5×
“Further, activation of PI3K has been shown to increase levels of HIF-1a, and these levels correlated with tumorigenicity and angiogenesis in nude mice.(18,19)”
BackgroundMethodInfluentialFolkman, J. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131306 · Cited by 1,209
Dimerization, DNA Binding, and Transactivation Properties of Hypoxia-inducible Factor 1
Jiang, B.-H., Rue, E., Wang, G. L., Roe, R., & Semenza, G. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.30.17771 · Cited by 1,106 · cited 1×
“HIF-1a stabilization can be induced by hypoxia, growth factors, and oncogenes.(17) Further, activation of PI3K has been shown to increase levels of HIF-1a, and these levels correlated with tumorigenicity and angiogenesis in nude mice.”
Background
Cited by
Nanomaterials for Theranostics: Recent Advances and Future Challenges
Lim, E.-K., Kim, T., Paik, S., Haam, S., Huh, Y.-M., & Lee, K. (2015) · Chemical Reviews · doi:10.1021/cr300213b · Cited by 1,233
Targeting fibrosis: mechanisms and clinical trials
Zhao, M., Wang, L., Wang, M., Zhou, S., Lu, Y., Cui, H., Racanelli, A. C., Zhang, L., Ye, T., Ding, B., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01070-3 · Cited by 547
Bauvois, B. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.10.001 · Cited by 543
Deryugina, E. I., & Quigley, J. P. (2015) · Matrix Biology · doi:10.1016/j.matbio.2015.04.004 · Cited by 422
Role of YKL-40 in the Angiogenesis, Radioresistance, and Progression of Glioblastoma
Francescone, R. A., Scully, S., Faibish, M., Taylor, S. L., Oh, D., Moral, L., Yan, W., Bentley, B., & Shao, R. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.212514 · Cited by 261
Antonov, A. S., Antonova, G. N., Munn, D. H., Mivechi, N., Lucas, R., Catravas, J. D., & Verin, A. D. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22356 · Cited by 128
Combination of nanotechnology with vascular targeting agents for effective cancer therapy
Jahanban‐Esfahlan, R., Seidi, K., Banimohamad‐Shotorbani, B., Jahanban‐Esfahlan, A., & Yousefi, B. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26051 · Cited by 84
EFEMP1 expression promotes angiogenesis and accelerates the growth of cervical cancer in vivo
Song, E.-L., Hou, Y.-P., Yu, S.-P., Chen, S.-G., Huang, J.-T., Luo, T., Kong, L.-P., Xu, J., & Wang, H.-Q. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.11.004 · Cited by 82
Metadata
- Authors
- Chetty, C., Lakka, S. S., Bhoopathi, P., & Rao, J. S.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2010-06-25
- Volume
- 127
- Issue
- 5
- Pages
- 1081-1095
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2075026880
- Cited by
- 205
- References
- 6
- FWCI
- 4.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.